Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 31 July 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Fecal microbiota transplant treats C. difficile in immunocompromised patients

A study in this month's issue of the American Journal of Gastroenterology examines fecal microbiota transplant for the treatment of Clostridium difficile infection in immunocompromised patients.

News image

Patients who are immunocompromised are at increased risk of Clostridium difficile infection (CDI), which has increased to epidemic proportions over the past decade.

Fecal microbiota transplantation (FMT) appears effective for the treatment of Clostridium difficile, although there is concern that immunocompromised patients may be at increased risk of having adverse events related to FMT.

Dr Colleen Kelly and colleagues from Rhode Island, USA describe the multicenter experience of FMT in immunocompromised patients.

A multicenter retrospective series was performed on the use of FMT in immunocompromised patients with Clostridium difficile that was recurrent, refractory, or severe.

The research team described rates of Clostridium difficile cure after FMT as well as adverse events experienced by immunocompromised patients after FMT.

79% were outpatients at the time of FMT
American Journal of Gastroenterology

A 32-item questionnaire soliciting demographic and pre- and post-FMT data was completed for 99 patients at 16 centers, of whom 80 were eligible for inclusion.

Outcomes included rates of Clostridium difficile cure after FMT, serious adverse events such as death or hospitalization within 12 weeks of FMT, infection within 12 weeks of FMT, and adverse events.

Cases included 75 adult and 5 pediatric patients treated with FMT for recurrent, refractory, and severe and/or overlap of recurrent/refractory and severe Clostridium difficile.
 
The team noted that in all, 79% were outpatients at the time of FMT.

The mean follow-up period between FMT and data collection was 11 months.

Reasons for immunocompromise included HIV/AIDS, solid organ transplant, oncologic condition, immunosuppressive therapy for inflammatory bowel disease, and other medical conditions/medications.

The research team found that the Clostridium difficile cure rate after a single FMT was 78%, with 62 patients suffering no recurrence at least 12 weeks post FMT.

The team identified 12 patients who underwent repeat FMT, of whom 8 had no further Clostridium difficile.

Thus, the overall cure rate was 89%.

The researchers found that 15% had any serious adverse event within 12 weeks post FMT, of which 10 were hospitalizations.

The team observed 2 deaths occurred within 12 weeks of FMT, one of which was the result of aspiration during sedation for FMT administered via colonoscopy, and the other was unrelated to FMT.

None suffered infections definitely related to FMT, but 2 patients developed unrelated infections and 5 had self-limited diarrheal illness in which no causal organism was identified.

The team found 1 patient had a superficial mucosal tear caused by the colonoscopy performed for the FMT, and 3 patients reported mild, self-limited abdominal discomfort post FMT.

About 14% of patients experienced disease flare post FMT.

The research team noted 3 ulcerative colitis patients that underwent colectomy related to course of UC >100 days after FMT.

Dr Kelly's team concludes, "This series demonstrates the effective use of FMT for Clostridium difficile in immunocompromized patients with few serious adverse events or related adverse events."

"Importantly, there were no related infectious complications in these high-risk patients."

Am J Gastroenterol 2014; 109:10651071
11 July 2014

Go to top of page Email this page Email this page to a colleague

 29 July 2016 
Susceptibility loci for gallstone disease
 29 July 2016 
H. pylori clarithromycin resistance in the USA
 29 July 2016 
Tool to diagnose Helicobacter-negative gastritis
 28 July 2016 
HCV eradication in cirrhotic patients
 28 July 2016 
Hep B screening and immunosuppressive therapy
 28 July 2016 
Pancreatitis after ERCP
 27 July 2016 
Gluten exposure in patients with celiac disease
 27 July 2016 
Bleeding GI recurrence with aspirin use
 27 July 2016 
IBD during pregnancy
 26 July 2016 
Gut microbiota and IBD
 26 July 2016 
Neighborhood variation in the use of laparoscopy for colon cancer
 26 July 2016 
Post-infectious IBS after C. diff
 25 July 2016 
Antibiotic prophylaxis for open colectomies
 25 July 2016 
Steroids in eosinophilic esophagitis
 25 July 2016 
Prevention of post-ERCP pancreatitis
 22 July 2016 
Upper GI lesions at primary diagnosis in IBD
 22 July 2016 
Duodenal villous atrophy and celiac disease
 22 July 2016 
Fecal calprotectin and IBD
 21 July 2016 
Radiofrequency ablation in Barrett's
 21 July 2016 
HCV eradication and inflammation in cirrhotic patients
 21 July 2016 
Surveillance of Barrett's
 20 July 2016 
Nonselective β-blockers and survival in cirrhosis
 20 July 2016 
Adolescent body mass index and and colorectal cancer risk
 20 July 2016 
Genetic biomarkers and IBD treatment response
 19 July 2016 
Prevention of chemotherapy-induced nausea and vomiting
 19 July 2016 
Screening diabetic patients for NAFLD
 19 July 2016 
Longterm clinical follow-up of living liver donors
 18 July 2016 
Rectal neuroendocrine tumors
 18 July 2016 
Liver cancer prediction scores in Hep B
 18 July 2016 
Liver stiffness measurement in chronic liver disease
 15 July 2016 
Patient reported outcomes in celiac disease
 15 July 2016 
Tonsillectomy and IBD risk
 15 July 2016 
Trainee IBD education in the USA
 14 July 2016 
Screening for familial pancreatic cancer
 14 July 2016 
Fecal calprotection for IBD prognosis
 14 July 2016 
Perianal surgery risk in Crohn's
 13 July 2016 
Psychological comorbidity and postinfectious IBS
 13 July 2016 
Lung transplant outcomes in Hep C
 13 July 2016 
Graft selection strategy in living donor liver transplants
 12 July 2016 
Surveillance endoscopy in Barrett's esophagus
 12 July 2016 
Therapy for iron deficiency anemia in IBD
 12 July 2016 
Treatment of pediatric acute liver failure
 11 July 2016 
Transition to adulthood in celiac disease
 11 July 2016 
Disturbed sleep and IBS
 11 July 2016 
Factors that influence access to liver transplant
 08 July 2016 
Mortality and peptic ulcers
 08 July 2016 
Genetic risk score and body mass index
 08 July 2016 
Statins and cirrhosis in Hep B
 07 July 2016 
Predicting food triggers in eosinophilic esophagitis
 07 July 2016 
Extraperitoneal vs transperitoneal colostomy for hernia
 07 July 2016 
Predictors fecal transplant failure in C. diff infection
 06 July 2016 
Therapies for Hep B cure
 06 July 2016 
Hospital volume and liver cancer survival
 06 July 2016 
Adverse events after outpatient colonoscopy
 05 July 2016 
Colorectal surgery and dialysis
 05 July 2016 
Exercise and gastroesophageal reflux
 05 July 2016 
Non-invasive scoring systems for fibrosis in NAFLD
 04 July 2016 
Autoimmunity in eosinophilic esophagitis and families
 04 July 2016 
Rectal cancer surgery checklist
 04 July 2016 
Guidelines on PPI and NSAID prescription

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us